In this article, we review the biology of TACI, focusing on its role in normal B and plasma cells and malignant MM cells, and also discuss various ways to incorporate TACI as a potential target for immunotherapies against MM. This evidence concerns the gene TNFRSF13B and Miyoshi myopathy.